|
1
|
Smith DA and Germolec DR: Introduction to
immunology and autoimmunity. Environ Health Perspect. 107 (Suppl
5):661–665. 1999.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mustafa ER, Firulescu SC, Parvanescu C,
Chisalau B, Tartea G, Efrem I, Barbulescu A, Dinescu S, Ciurea P,
Radu L, et al: Triple valve infective endocarditis - a late
diagnosis. J Mind Med Sci. 5:141–144. 2018.
|
|
3
|
Firulescu SC, Tudoraşcu DR, Pârvănescu CD,
Chisălău AB, Bastian AE, Efrem IC, Bărbulescu AL, Forţofoiu MC,
Criveanu C, Ionescu P, et al: The role of skin and muscle biopsy in
the diagnosis of main connective tissue diseases. Rom J Morphol
Embryol. 59:55–64. 2018.PubMed/NCBI
|
|
4
|
Schwartz DM, Bonelli M, Gadina M and
O'Shea JJ: Type I/II cytokines, JAKs, and new strategies for
treating autoimmune diseases. Nat Rev Rheumatol. 12:25–36.
2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Schwartz DM, Kanno Y, Villarino A, Ward M,
Gadina M and O'Shea JJ: JAK inhibition as a therapeutic strategy
for immune and inflammatory diseases. Nat Rev Drug Discov.
17(78)2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Fleischmann R, Mysler E, Hall S, Kivitz
AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R and Takiya L: and
ORAL Strategy investigators. Efficacy and safety of tofacitinib
monotherapy, tofacitinib with methotrexate, and adalimumab with
methotrexate in patients with rheumatoid arthritis (ORAL Strategy):
a phase 3b/4, double-blind, head-to-head, randomised controlled
trial. Lancet. 390:457–468. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Fleischmann R, Kremer J, Cush J,
Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV,
Zwillich SH and Kanik KS: ORAL Solo Investigators.
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid
arthritis. N Engl J Med. 367:495–507. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Vieira MC, Zwillich SH, Jansen JP,
Smiechowski B, Spurden D and Wallenstein GV: Tofacitinib versus
biologic treatments in patients with active rheumatoid arthritis
who have had an inadequate response to tumor necrosis factor
inhibitors: Results from a network meta-analysis. Clin Ther.
38:2628–2641.e5. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Eisenstein EM and Berkun Y: Diagnosis and
classification of juvenile idiopathic arthritis. J Autoimmun.
48-49:31–33. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Giancane G, Consolaro A, Lanni S, Davì S,
Schiappapietra B and Ravelli A: Juvenile idiopathic arthritis:
Diagnosis and treatment. Rheumatol Ther. 3:187–207. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Clark JD, Flanagan ME and Telliez JB:
Discovery and development of Janus kinase (JAK) inhibitors for
inflammatory diseases. J Med Chem. 57:5023–5038. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Platanitis E, Demiroz D, Schneller A,
Fischer K, Capelle C, Hartl M, Gossenreiter T, Müller M,
Novatchkova M and Decker T: A molecular switch from STAT2-IRF9 to
ISGF3 underlies interferon-induced gene transcription. Nat Commun.
10(2921)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Schindler C, Levy DE and Decker T:
JAK-STAT signaling: From interferons to cytokines. J Biol Chem.
282:20059–20063. 2007.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Fragoulis GE, McInnes IB and Siebert S:
JAK-inhibitors. New players in the field of immune-mediated
diseases, beyond rheumatoid arthritis. Rheumatology (Oxford). 58
(Suppl 1):i43–i54. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Calabresi E, Petrelli F, Bonifacio AF,
Puxeddu I and Alunno A: One year in review 2018: Pathogenesis of
rheumatoid arthritis. Clin Exp Rheumatol. 36:175–184.
2018.PubMed/NCBI
|
|
16
|
Itoh I, Kasuno K, Yamamoto C, Takahashi N,
Shimizu H, Ojima T, Hayashi S, Kimura H and Iwano M: IgA vasculitis
developed as an adverse effect of tofacitinib taken for rheumatoid
arthritis. Intern Med. 59:817–821. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Silosi I, Cojocaru M, Foia L, Boldeanu MV,
Petrescu F, Surlin P and Biciusca V: Significance of circulating
and crevicular matrix metalloproteinase-9 in rheumatoid
arthritis-chronic periodontitis association. J Immunol Res.
2015(218060)2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Albu CV, Padureanu V, Boldeanu MV, Bumbea
AM, Enescu AS, Albulescu DM, Silosi CA and Enescu A: Vascular
neurocognitive disorders and the vascular risk factors. J Mind Med
Sci. 5:7–15. 2018.
|
|
19
|
Barbulescu AL, Ciurea PL, Mitran C,
Chisalau BA, Parvanescu CD, Firulescu SC, Balasoiu M, Boldeanu MV,
Popoviciu H and Vreju FA: High frequency ultrasonography of the
hand versus anti-RA33 evaluation in early rheumatoid arthritis - a
pilot study. Med Ultrason. 19:166–171. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Son HJ, Lee SH, Lee SY, Kim EK, Yang EJ,
Kim JK, Seo HB, Park SH, Cho ML and Oncostatin M: Correction:
Oncostatin M suppresses activation of IL-17/Th17 via SOCS3
regulation in CD4+ T cells. J Immunol.
198(4879)2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
White UA and Stephens JM: The gp130
receptor cytokine family: Regulators of adipocyte development and
function. Curr Pharm Des. 17:340–346. 2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lou L, Zhou J, Liu Y, Wei YI, Zhao J, Deng
J, Dong B, Zhu L, Wu A, Yang Y, et al: Chlorogenic acid induces
apoptosis to inhibit inflammatory proliferation of IL-6-induced
fibroblast-like synoviocytes through modulating the activation of
JAK/STAT and NF-κB signaling pathways. Exp Ther Med. 11:2054–2060.
2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mihara M, Hashizume M, Yoshida H, Suzuki M
and Shiina M: IL-6/IL-6 receptor system and its role in
physiological and pathological conditions. Clin Sci (Lond).
122:143–159. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sheppard M, Laskou F, Stapleton PP, Hadavi
S and Dasgupta B: Tocilizumab (Actemra). Hum Vaccin Immunother.
13:1972–1988. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
McGovern JL and Notley CA: Production of
IL-17: What's STAT got to do with it? JAK-STAT. 1:80–82.
2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Siloşi I, Boldeanu MV, Cojocaru M,
Biciuşcă V, Pădureanu V, Bogdan M, Badea RG, Avramescu C, Petrescu
IO, Petrescu F, et al: The relationship of cytokines IL-13 and
IL-17 with autoantibodies profile in early rheumatoid arthritis. J
Immunol Res. 2016(3109135)2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Siloşi I, Boldeanu L, Biciuşcă V, Bogdan
M, Avramescu C, Taisescu C, Padureanu V, Boldeanu MV, Dricu A and
Siloşi CA: Serum biomarkers for discrimination between hepatitis
C-related arthropathy and early rheumatoid arthritis. Int J Mol
Sci. 18(E1304)2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
van Hamburg JP and Tas SW: Molecular
mechanisms underpinning T helper 17 cell heterogeneity and
functions in rheumatoid arthritis. J Autoimmun. 87:69–81.
2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
López de Padilla CM and Niewold TB: The
type I interferons: Basic concepts and clinical relevance in
immune-mediated inflammatory diseases. Gene. 576:14–21.
2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Stanifer ML, Pervolaraki K and Boulant S:
Differential regulation of type I and type III interferon
signaling. Int J Mol Sci. 20(1445)2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zuo J, Xia Y, Li X, Ou-Yang Z and Chen JW:
Selective modulation of MAPKs contribute to the anti-proliferative
and anti-inflammatory activities of
1,7-dihydroxy-3,4-dimethoxyxanthone in rheumatoid arthritis-derived
fibroblast-like synoviocyte MH7A cells. J Ethnopharmacol.
168:248–254. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Malemud CJ: The role of the JAK/STAT
signal pathway in rheumatoid arthritis. Ther Adv Musculoskelet Dis.
10:117–127. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Mori M, Hashimoto M, Matsuo T, Fujii T,
Furu M, Ito H, Yoshitomi H, Hirose J, Ito Y, Akizuki S, et al:
Cell-contact- dependent activation of CD4+ T cells by
adhesion molecules on synovial fibroblasts. Mod Rheumatol.
27:448–456. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Hammaker D, Nygaard G, Kuhs A, Ai R, Boyle
DL, Wang W and Firestein GS: Joint location-specific JAK-STAT
signaling in rheumatoid arthritis fibroblast-like synoviocytes. ACR
Open Rheumatol. 1:640–648. 2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
O'Shea JJ, Schwartz DM, Villarino AV,
Gadina M, McInnes IB and Laurence A: The JAK-STAT pathway: Impact
on human disease and therapeutic intervention. Annu Rev Med.
66:311–328. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Busch-Dienstfertig M and
González-Rodríguez S: IL-4, JAK-STAT signaling, and pain. JAK-STAT.
2(e27638)2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Bauer S, Kerr BJ and Patterson PH: The
neuropoietic cytokine family in development, plasticity, disease
and injury. Nat Rev Neurosci. 8:221–232. 2007.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Tan S, Xu J, Lai A, Cui R, Bai R, Li S,
Liang W, Zhang G, Jiang S, Liu S, et al: Curculigoside exerts
significant anti arthritic effects in vivo and in
vitro via regulation of the JAK/STAT/NF κB signaling pathway.
Mol Med Rep. 19:2057–2064. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Maeshima K, Yamaoka K, Kubo S, Nakano K,
Iwata S, Saito K, Ohishi M, Miyahara H, Tanaka S, Ishii K, et al:
The JAK inhibitor tofacitinib regulates synovitis through
inhibition of interferon-γ and interleukin-17 production by human
CD4+ T cells. Arthritis Rheum. 64:1790–1798.
2012.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Salaffi F, Giacobazzi G and Di Carlo M:
Chronic pain in inflammatory arthritis: Mechanisms, metrology, and
emerging targets - a focus on the JAK-STAT pathway. Pain Res Manag.
2018(8564215)2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Dutzmann J, Daniel JM, Bauersachs J,
Hilfiker-Kleiner D and Sedding DG: Emerging translational
approaches to target STAT3 signalling and its impact on vascular
disease. Cardiovasc Res. 106:365–374. 2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Caruntu C, Boda D, Dumitrascu G,
Constantin C and Neagu M: Proteomics focusing on immune markers in
psoriatic arthritis. Biomarkers Med. 9:513–528. 2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Negrei C, Arsene AL, Toderescu CD, Boda D
and Ilie M: Acitretin treatment may influence the cell membrane
fluidity. Farmacia. 60:767–772. 2012.
|
|
44
|
Negrei C, Ginghină O, Caruntu C, Burcea
Dragomiroiu G, Jinescu G and Boda D: Investigation relevance of
methotrexate polyglutamates in biological systems by high
performance liquid chromatography. Rev Chim-Bucharest. 66:766–768.
2015.
|
|
45
|
Negrei C, Caruntu C, Ginghina O,
Dragomiroiu GT, Toderescu CD and Boda D: Qualitative and
quantitative determination of methotrexate polyglutamates in
erythrocytes by high performance liquid chromatography. Rev
Chim-Bucharest. 66:607–610. 2015.
|
|
46
|
Boda D, Negrei C, Nicolescu F and Badalau
C: Assessment of some oxidative stress parameters in methotrexate
treated psoriasis patients. Farmacia. 62:704–710. 2014.
|
|
47
|
Silvagni E, Di Battista M, Bonifacio AF,
Zucchi D, Governato G and Scirè CA: One year in review 2019:
Novelties in the treatment of rheumatoid arthritis. Clin Exp
Rheumatol. 37:519–534. 2019.PubMed/NCBI
|
|
48
|
Choy EH: Clinical significance of Janus
kinase inhibitor selectivity. Rheumatology (Oxford). 58:953–962.
2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Hodge JA, Kawabata TT, Krishnaswami S,
Clark JD, Telliez JB, Dowty ME, Menon S, Lamba M and Zwillich S:
The mechanism of action of tofacitinib - an oral Janus kinase
inhibitor for the treatment of rheumatoid arthritis. Clin Exp
Rheumatol. 34:318–328. 2016.PubMed/NCBI
|
|
50
|
Rigby WFC, Lampl K, Low JM and Furst DE:
Review of routine laboratory monitoring for patients with
rheumatoid arthritis receiving biologic or nonbiologic DMARDs. Int
J Rheumatol. 2017(9614241)2017.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Banerjee S, Biehl A, Gadina M, Hasni S and
Schwartz DM: JAK-STAT signaling as a target for inflammatory and
autoimmune diseases: Current and future prospects. Drugs.
77:521–546. 2017.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Jegatheeswaran J, Turk M and Pope JE:
Comparison of Janus kinase inhibitors in the treatment of
rheumatoid arthritis: A systemic literature review. Immunotherapy.
11:737–754. 2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Taylor PC: Clinical efficacy of launched
JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 58
(Suppl 1):i17–i26. 2019.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Borie DC, Larson ML, Flores MG, Campbell
A, Rousvoal G, Zhang S, Higgins JP, Ball DJ, Kudlacz EM, Brissette
WH, et al: Combined use of the JAK3 inhibitor CP-690,550 with
mycophenolate mofetil to prevent kidney allograft rejection in
nonhuman primates. Transplantation. 80:1756–1764. 2005.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Zerbini CA and Lomonte AB: Tofacitinib for
the treatment of rheumatoid arthritis. Expert Rev Clin Immunol.
8:319–331. 2012.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Kremer JM, Bloom BJ, Breedveld FC, Coombs
JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R,
Wilkinson B, Zerbini CA, et al: Tofacitinib Study Investigators:
The safety and efficacy of a JAK inhibitor in patients with active
rheumatoid arthritis: Results of a double-blind, placebo-controlled
phase IIa trial of three dosage levels of CP-690,550 versus
placebo. Arthritis Rheum. 60:1895–1905. 2009.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Tanaka Y, Suzuki M, Nakamura H, Toyoizumi
S and Zwillich SH: Tofacitinib Study Investigators. Phase II study
of tofacitinib (CP-690,550) combined with methotrexate in patients
with rheumatoid arthritis and an inadequate response to
methotrexate. Arthritis Care Res (Hoboken). 63:1150–1158.
2011.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Fleischmann R, Cutolo M, Genovese MC, Lee
EB, Kanik KS, Sadis S, Connell CA, Gruben D, Krishnaswami S,
Wallenstein G, et al: Phase IIb dose-ranging study of the oral JAK
inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus
placebo in patients with active rheumatoid arthritis with an
inadequate response to disease-modifying antirheumatic drugs.
Arthritis Rheum. 64:617–629. 2012.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Mogul A, Corsi K and McAuliffe L:
Baricitinib: The second FDA-approved JAK inhibitor for the
treatment of rheumatoid arthritis. Ann Pharmacother. 53:947–953.
2019.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Kubo S, Nakayamada S and Tanaka Y:
Baricitinib for the treatment of rheumatoid arthritis. Expert Rev
Clin Immunol. 12:911–919. 2016.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Al-Salama ZT and Scott LJ: Baricitinib: A
review in rheumatoid arthritis. Drugs. 78:761–772. 2018.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Biggioggero M, Becciolini A, Crotti C,
Agape E and Favalli EG: Upadacitinib and filgotinib: The role of
JAK1 selective inhibition in the treatment of rheumatoid arthritis.
Drugs Context. 8(212595)2019.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Takeuchi T, Tanaka Y, Iwasaki M, Ishikura
H, Saeki S and Kaneko Y: Efficacy and safety of the oral Janus
kinase inhibitor peficitinib (ASP015K) monotherapy in patients with
moderate to severe rheumatoid arthritis in Japan: A 12-week,
randomised, double-blind, placebo-controlled phase IIb study. Ann
Rheum Dis. 75:1057–1064. 2016.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Quintás-Cardama A, Kantarjian H, Cortes J
and Verstovsek S: Janus kinase inhibitors for the treatment of
myeloproliferative neoplasias and beyond. Nat Rev Drug Discov.
10:127–140. 2011.PubMed/NCBI View Article : Google Scholar
|
|
65
|
MacFarlane LA and Todd DJ: Kinase
inhibitors: The next generation of therapies in the treatment of
rheumatoid arthritis. Int J Rheum Dis. 17:359–368. 2014.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Gadina M, Schwartz DM and O'Shea JJ:
Decernotinib: A next-generation Jakinib. Arthritis Rheumatol.
68:31–34. 2016.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Genovese MC, van Vollenhoven RF,
Pacheco-Tena C, Zhang Y and Kinnman N: VX-509 (decernotinib), an
oral selective JAK-3 inhibitor, in combination with methotrexate in
patients with rheumatoid arthritis. Arthritis Rheumatol. 68:46–55.
2016.PubMed/NCBI View Article : Google Scholar
|
